2025-03-11 23:53:17
Latest Post
Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
REC Limited inaugurates REC Experience Center
Hexaware Inaugurates Global Business Headquarters in Jersey City
HCLTech among Ethisphere's 2025 World's Most Ethical Companies®
Ind-Swift Laboratories Ltd receives 'Best Employer Brand - Punjab 2025' by World HRD Congress
Stock Report
Gland Pharma Ltd reports consolidated PAT of Rs. 78.68 crores in Q4 FY2022-23
Posted On : 2023-05-18 22:43:43( TIMEZONE : IST )
Gland Pharma Limited has reported Consolidated financial results for the period ended March 31, 2023.
Financial Results (Q4 FY2023) - QoQ Comparison
The company has reported total income of Rs. 823.950 crores during the period ended March 31, 2023 as compared to Rs. 999.797 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs. 78.683 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs. 231.949 crores for the period ended December 31, 2022.
The company has reported EPS of Rs. 4.78 for the period ended March 31, 2023 as compared to Rs. 14.08 for the period ended December 31, 2022.
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹823.950 crs | ₹999.797 crs |  -17.59% |
| Net Profit | ₹78.683 crs | ₹231.949 crs | -66.08% |
| EPS | ₹4.78 | ₹14.08 | -66.05% |
Financial Results (Q4 FY2023) - YoY Comparison
The company has reported total income of Rs.823.950 crores during the period ended March 31, 2023 as compared to Rs.1168.248 crores during the period ended March 31, 2022.
The company has posted net profit / (loss) of Rs.78.683 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs.285.902 crores for the period ended March 31, 2022.
The company has reported EPS of Rs.4.78 for the period ended March 31, 2023 as compared to Rs.17.36 for the period ended March 31, 2022.
| Financials | Q4 FY2023 | Q4 FY2022 | % Change |
| Total Income | ₹823.950 crs | ₹1168.248 crs | -29.47% |
| Net Profit | ₹78.683 crs | ₹285.902 crs | -72.48% |
| EPS | ₹4.78 | ₹17.36 | -72.47% |
Financial Results (Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.3865.064 crores during the Financial Year ended March 31, 2023 as compared to Rs.4624.646 crores during the Financial Year ended March 31, 2022.
The company has posted net profit / (loss) of Rs.781.043 crores for the Financial Year ended March 31, 2023 as against net profit / (loss) of Rs.1211.664 crores for the Financial Year ended March 31, 2022.
The company has reported EPS of Rs.47.43 for the Financial Year ended March 31, 2023 as compared to Rs.73.64 for the Financial Year ended March 31, 2022.
| Financials | Year Ended FY2023 | Year Ended FY2022 | % Change |
| Total Income | ₹3865.064 crs | ₹4624.646 crs | -16.42% |
| Net Profit | ₹781.043 crs | ₹1211.664 crs | -35.54% |
| EPS | ₹47.43 | ₹73.64 | -35.59% |
Shares of Gland Pharma Limited was last trading in BSE at Rs. 1338.50 as compared to the previous close of Rs. 1337.95. The total number of shares traded during the day was 11631 in over 1344 trades.
The stock hit an intraday high of Rs. 1377.25 and intraday low of 1321.25. The net turnover during the day was Rs. 15662275.00.
